Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO31073 | Ligusticum chuanxiong | Species | Apiaceae | Eukaryota | TCM_Taiwan* |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT1654 | Individual Protein | Urokinase-type plasminogen activator | Homo sapiens | IC50 | = | 200000 | nM | 11052791 |
NPT2645 | Organism | Giardia intestinalis | Giardia intestinalis | IC50 | = | 1902 | nM | 12127542 |
NPT992 | Organism | Entamoeba histolytica | Entamoeba histolytica | IC50 | = | 114 | nM | 12127542 |
NPT992 | Organism | Entamoeba histolytica | Entamoeba histolytica | IC50 | = | 114.82 | nM | 17074492 |
NPT6015 | Individual Protein | Pteridine reductase, putative | Trypanosoma brucei brucei (strain 927/4 GUTat10.1) | Ki | = | 288000 | nM | 19527033 |
NPT347 | Cell Line | Lymphoblastoid cells | Homo sapiens | Potency | = | 31622.8 | nM | PubChem BioAssay data set |
NPT94 | Individual Protein | Aldehyde dehydrogenase 1A1 | Homo sapiens | Potency | = | 19952.6 | nM | PubChem BioAssay data set |
NPT197 | Protein-Protein Interaction | Menin/Histone-lysine N-methyltransferase MLL | Homo sapiens | Potency | = | 19952.6 | nM | PubChem BioAssay data set |
NPT1098 | Individual Protein | Eyes absent homolog 2 | Homo sapiens | Potency | 19952.6 | nM | PubChem BioAssay data set | |
NPT546 | Individual Protein | Retinoid X receptor alpha | Homo sapiens | Potency | 31622.8 | nM | PubChem BioAssay data set | |
NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | 28183.8 | nM | PubChem BioAssay data set | |
NPT106 | Individual Protein | Peroxisome proliferator-activated receptor delta | Homo sapiens | Potency | 11220.2 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 6513.1 | nM | PubChem BioAssay data set | ||
NPT4106 | Individual Protein | Amine oxidase, copper containing | Homo sapiens | IC50 | = | 4100 | nM | 23664164 |
NPT6017 | Individual Protein | Amine oxidase, copper containing | Rattus norvegicus | IC50 | = | 1000 | nM | 23664164 |
NPT2 | Others | Unspecified | Ki | = | 228000 | nM | 24015767 | |
NPT2 | Others | Unspecified | Potency | 12328.4 | nM | PubChem BioAssay data set | ||
NPT444 | Individual Protein | Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens | Potency | 177.8 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 30700.2 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 38100.6 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 77115.4 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 545.9 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 30264.4 | nM | PubChem BioAssay data set | ||
NPT317 | Uncleic Acid | Nucleic Acid | IC50 | > | 11000000 | nM | 25466178 | |
NPT163 | Individual Protein | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | Potency | 24598.3 | nM | PubChem BioAssay data set | |
NPT163 | Individual Protein | Nuclear factor NF-kappa-B p105 subunit | Homo sapiens | Potency | 68346.6 | nM | PubChem BioAssay data set | |
NPT74 | Individual Protein | Proto-oncogene c-JUN | Homo sapiens | Potency | 43123.8 | nM | PubChem BioAssay data set | |
NPT74 | Individual Protein | Proto-oncogene c-JUN | Homo sapiens | Potency | 49080.1 | nM | PubChem BioAssay data set | |
NPT2 | Others | Unspecified | Potency | 24250.3 | nM | PubChem BioAssay data set | ||
NPT2 | Others | Unspecified | Potency | 24598.3 | nM | PubChem BioAssay data set |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC317642 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
0.75 | Intermediate Similarity | NPC134825 |
0.7347 | Intermediate Similarity | NPC229477 |
0.7222 | Intermediate Similarity | NPC474430 |
0.7193 | Intermediate Similarity | NPC314141 |
0.7155 | Intermediate Similarity | NPC125416 |
0.7143 | Intermediate Similarity | NPC271732 |
0.7109 | Intermediate Similarity | NPC216159 |
0.7091 | Intermediate Similarity | NPC313362 |
0.7021 | Intermediate Similarity | NPC301874 |
0.6791 | Remote Similarity | NPC42483 |
0.6737 | Remote Similarity | NPC66775 |
0.6731 | Remote Similarity | NPC173991 |
0.6594 | Remote Similarity | NPC114209 |
0.6435 | Remote Similarity | NPC24060 |
0.6325 | Remote Similarity | NPC302790 |
0.6325 | Remote Similarity | NPC164802 |
0.6279 | Remote Similarity | NPC145754 |
0.6275 | Remote Similarity | NPC307456 |
0.6261 | Remote Similarity | NPC328877 |
0.6226 | Remote Similarity | NPC262295 |
0.6204 | Remote Similarity | NPC92689 |
0.619 | Remote Similarity | NPC475915 |
0.6179 | Remote Similarity | NPC313673 |
0.6154 | Remote Similarity | NPC75999 |
0.6154 | Remote Similarity | NPC15839 |
0.614 | Remote Similarity | NPC326792 |
0.6122 | Remote Similarity | NPC300238 |
0.6111 | Remote Similarity | NPC315403 |
0.6102 | Remote Similarity | NPC434 |
0.6102 | Remote Similarity | NPC20322 |
0.6102 | Remote Similarity | NPC79618 |
0.6099 | Remote Similarity | NPC204141 |
0.6098 | Remote Similarity | NPC143156 |
0.6098 | Remote Similarity | NPC288232 |
0.6075 | Remote Similarity | NPC43655 |
0.6055 | Remote Similarity | NPC191444 |
0.6053 | Remote Similarity | NPC75496 |
0.6031 | Remote Similarity | NPC469949 |
0.6019 | Remote Similarity | NPC111233 |
0.6019 | Remote Similarity | NPC30445 |
0.5963 | Remote Similarity | NPC240134 |
0.5963 | Remote Similarity | NPC176858 |
0.5963 | Remote Similarity | NPC107135 |
0.5954 | Remote Similarity | NPC252794 |
0.5948 | Remote Similarity | NPC291610 |
0.5942 | Remote Similarity | NPC125746 |
0.5935 | Remote Similarity | NPC296163 |
0.5893 | Remote Similarity | NPC322040 |
0.5893 | Remote Similarity | NPC469330 |
0.5872 | Remote Similarity | NPC297532 |
0.5871 | Remote Similarity | NPC314557 |
0.5846 | Remote Similarity | NPC41174 |
0.5811 | Remote Similarity | NPC120070 |
0.5804 | Remote Similarity | NPC108800 |
0.5796 | Remote Similarity | NPC315715 |
0.5794 | Remote Similarity | NPC84268 |
0.5776 | Remote Similarity | NPC213774 |
0.5766 | Remote Similarity | NPC78154 |
0.5762 | Remote Similarity | NPC470204 |
0.5752 | Remote Similarity | NPC476483 |
0.5748 | Remote Similarity | NPC192209 |
0.5735 | Remote Similarity | NPC476687 |
0.5735 | Remote Similarity | NPC476689 |
0.5735 | Remote Similarity | NPC476685 |
0.5725 | Remote Similarity | NPC254698 |
0.5724 | Remote Similarity | NPC253687 |
0.5724 | Remote Similarity | NPC470203 |
0.5705 | Remote Similarity | NPC476297 |
0.5705 | Remote Similarity | NPC476219 |
0.5683 | Remote Similarity | NPC198988 |
0.568 | Remote Similarity | NPC187036 |
0.5672 | Remote Similarity | NPC250361 |
0.5652 | Remote Similarity | NPC316104 |
0.5652 | Remote Similarity | NPC162417 |
0.5643 | Remote Similarity | NPC325252 |
0.5643 | Remote Similarity | NPC218268 |
0.563 | Remote Similarity | NPC209389 |
0.5625 | Remote Similarity | NPC313449 |
0.5625 | Remote Similarity | NPC31651 |
0.562 | Remote Similarity | NPC22079 |
0.5616 | Remote Similarity | NPC143872 |
0.5614 | Remote Similarity | NPC7067 |
0.5606 | Remote Similarity | NPC283130 |
0.5606 | Remote Similarity | NPC328683 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC317642 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.802 | Intermediate Similarity | NPD9270 | Clinical (unspecified phase) |
0.7477 | Intermediate Similarity | NPD526 | Approved |
0.7411 | Intermediate Similarity | NPD560 | Approved |
0.7411 | Intermediate Similarity | NPD561 | Approved |
0.7377 | Intermediate Similarity | NPD3424 | Clinical (unspecified phase) |
0.7282 | Intermediate Similarity | NPD462 | Approved |
0.7282 | Intermediate Similarity | NPD463 | Approved |
0.7282 | Intermediate Similarity | NPD464 | Approved |
0.7273 | Intermediate Similarity | NPD1949 | Approved |
0.7273 | Intermediate Similarity | NPD1950 | Approved |
0.7265 | Intermediate Similarity | NPD764 | Phase 3 |
0.7179 | Intermediate Similarity | NPD9700 | Clinical (unspecified phase) |
0.7165 | Intermediate Similarity | NPD1515 | Discontinued |
0.7155 | Intermediate Similarity | NPD9719 | Approved |
0.7155 | Intermediate Similarity | NPD5243 | Approved |
0.7155 | Intermediate Similarity | NPD5244 | Approved |
0.7155 | Intermediate Similarity | NPD5245 | Approved |
0.7155 | Intermediate Similarity | NPD9720 | Approved |
0.7049 | Intermediate Similarity | NPD3080 | Clinical (unspecified phase) |
0.7034 | Intermediate Similarity | NPD541 | Approved |
0.7034 | Intermediate Similarity | NPD726 | Discontinued |
0.7 | Intermediate Similarity | NPD1728 | Clinical (unspecified phase) |
0.6942 | Remote Similarity | NPD9527 | Approved |
0.6942 | Remote Similarity | NPD9528 | Approved |
0.6864 | Remote Similarity | NPD2464 | Approved |
0.6864 | Remote Similarity | NPD2463 | Approved |
0.6864 | Remote Similarity | NPD2467 | Approved |
0.6791 | Remote Similarity | NPD9724 | Phase 1 |
0.6696 | Remote Similarity | NPD1539 | Approved |
0.6639 | Remote Similarity | NPD202 | Clinical (unspecified phase) |
0.6637 | Remote Similarity | NPD233 | Clinical (unspecified phase) |
0.6529 | Remote Similarity | NPD153 | Clinical (unspecified phase) |
0.6496 | Remote Similarity | NPD909 | Clinical (unspecified phase) |
0.6446 | Remote Similarity | NPD1171 | Approved |
0.6435 | Remote Similarity | NPD990 | Approved |
0.6435 | Remote Similarity | NPD993 | Approved |
0.6422 | Remote Similarity | NPD9188 | Approved |
0.6418 | Remote Similarity | NPD2528 | Approved |
0.6393 | Remote Similarity | NPD299 | Phase 3 |
0.6378 | Remote Similarity | NPD2143 | Discontinued |
0.6349 | Remote Similarity | NPD2964 | Clinical (unspecified phase) |
0.6336 | Remote Similarity | NPD2033 | Phase 2 |
0.6325 | Remote Similarity | NPD477 | Phase 1 |
0.6324 | Remote Similarity | NPD7044 | Discontinued |
0.6288 | Remote Similarity | NPD809 | Discontinued |
0.6281 | Remote Similarity | NPD1813 | Discontinued |
0.6269 | Remote Similarity | NPD2867 | Approved |
0.6269 | Remote Similarity | NPD2399 | Clinical (unspecified phase) |
0.6268 | Remote Similarity | NPD9709 | Approved |
0.6268 | Remote Similarity | NPD9708 | Approved |
0.6262 | Remote Similarity | NPD297 | Approved |
0.6262 | Remote Similarity | NPD9350 | Approved |
0.6262 | Remote Similarity | NPD9348 | Approved |
0.6262 | Remote Similarity | NPD9349 | Approved |
0.6262 | Remote Similarity | NPD9351 | Phase 3 |
0.6262 | Remote Similarity | NPD9 | Approved |
0.626 | Remote Similarity | NPD4866 | Approved |
0.626 | Remote Similarity | NPD4867 | Approved |
0.626 | Remote Similarity | NPD3841 | Phase 3 |
0.625 | Remote Similarity | NPD9304 | Approved |
0.6207 | Remote Similarity | NPD2927 | Phase 3 |
0.617 | Remote Similarity | NPD4402 | Clinical (unspecified phase) |
0.6165 | Remote Similarity | NPD1316 | Discontinued |
0.6148 | Remote Similarity | NPD2032 | Discontinued |
0.614 | Remote Similarity | NPD479 | Approved |
0.6132 | Remote Similarity | NPD305 | Approved |
0.6132 | Remote Similarity | NPD304 | Approved |
0.6115 | Remote Similarity | NPD2129 | Approved |
0.6111 | Remote Similarity | NPD9108 | Approved |
0.6102 | Remote Similarity | NPD1054 | Approved |
0.6102 | Remote Similarity | NPD458 | Approved |
0.6068 | Remote Similarity | NPD156 | Phase 3 |
0.6033 | Remote Similarity | NPD3001 | Approved |
0.6033 | Remote Similarity | NPD2999 | Approved |
0.6031 | Remote Similarity | NPD6713 | Approved |
0.6031 | Remote Similarity | NPD6712 | Approved |
0.6029 | Remote Similarity | NPD6102 | Clinical (unspecified phase) |
0.6026 | Remote Similarity | NPD2478 | Clinical (unspecified phase) |
0.6026 | Remote Similarity | NPD2392 | Clinical (unspecified phase) |
0.6016 | Remote Similarity | NPD9598 | Discontinued |
0.6 | Remote Similarity | NPD8128 | Discontinued |
0.5987 | Remote Similarity | NPD773 | Approved |
0.5986 | Remote Similarity | NPD2529 | Approved |
0.5984 | Remote Similarity | NPD1299 | Clinical (unspecified phase) |
0.5971 | Remote Similarity | NPD3625 | Discontinued |
0.597 | Remote Similarity | NPD988 | Discontinued |
0.5969 | Remote Similarity | NPD3623 | Clinical (unspecified phase) |
0.5969 | Remote Similarity | NPD3622 | Clinical (unspecified phase) |
0.5968 | Remote Similarity | NPD1720 | Phase 2 |
0.5968 | Remote Similarity | NPD1723 | Phase 2 |
0.5966 | Remote Similarity | NPD445 | Discontinued |
0.5966 | Remote Similarity | NPD1112 | Phase 3 |
0.5966 | Remote Similarity | NPD1111 | Phase 3 |
0.596 | Remote Similarity | NPD509 | Phase 3 |
0.5957 | Remote Similarity | NPD9254 | Phase 3 |
0.5954 | Remote Similarity | NPD1836 | Discontinued |
0.5954 | Remote Similarity | NPD6900 | Discontinued |
0.5952 | Remote Similarity | NPD1216 | Clinical (unspecified phase) |
0.5948 | Remote Similarity | NPD707 | Approved |
0.5942 | Remote Similarity | NPD544 | Clinical (unspecified phase) |
0.5938 | Remote Similarity | NPD4811 | Discontinued |
0.5935 | Remote Similarity | NPD1311 | Approved |
0.5932 | Remote Similarity | NPD414 | Discontinued |
0.5926 | Remote Similarity | NPD3652 | Approved |
0.5921 | Remote Similarity | NPD6767 | Clinical (unspecified phase) |
0.592 | Remote Similarity | NPD6070 | Approved |
0.592 | Remote Similarity | NPD6069 | Approved |
0.5902 | Remote Similarity | NPD3865 | Approved |
0.5896 | Remote Similarity | NPD1619 | Phase 3 |
0.5893 | Remote Similarity | NPD243 | Approved |
0.5893 | Remote Similarity | NPD8 | Approved |
0.589 | Remote Similarity | NPD2660 | Approved |
0.589 | Remote Similarity | NPD2128 | Phase 1 |
0.589 | Remote Similarity | NPD2662 | Approved |
0.5882 | Remote Similarity | NPD261 | Approved |
0.5878 | Remote Similarity | NPD4985 | Clinical (unspecified phase) |
0.5877 | Remote Similarity | NPD9352 | Approved |
0.5873 | Remote Similarity | NPD2638 | Clinical (unspecified phase) |
0.5865 | Remote Similarity | NPD2036 | Approved |
0.5862 | Remote Similarity | NPD499 | Phase 3 |
0.5859 | Remote Similarity | NPD6892 | Discontinued |
0.5857 | Remote Similarity | NPD9245 | Clinical (unspecified phase) |
0.5857 | Remote Similarity | NPD174 | Discontinued |
0.5855 | Remote Similarity | NPD1313 | Approved |
0.5846 | Remote Similarity | NPD5787 | Discontinued |
0.5845 | Remote Similarity | NPD2866 | Approved |
0.5841 | Remote Similarity | NPD665 | Phase 2 |
0.5839 | Remote Similarity | NPD212 | Discontinued |
0.5833 | Remote Similarity | NPD278 | Approved |
0.5833 | Remote Similarity | NPD6299 | Approved |
0.5833 | Remote Similarity | NPD3240 | Phase 2 |
0.5833 | Remote Similarity | NPD6300 | Approved |
0.5833 | Remote Similarity | NPD1569 | Phase 2 |
0.5833 | Remote Similarity | NPD1824 | Discontinued |
0.5833 | Remote Similarity | NPD5253 | Approved |
0.5833 | Remote Similarity | NPD9499 | Clinical (unspecified phase) |
0.5828 | Remote Similarity | NPD1015 | Phase 2 |
0.5828 | Remote Similarity | NPD1016 | Phase 2 |
0.5821 | Remote Similarity | NPD8263 | Discontinued |
0.5812 | Remote Similarity | NPD708 | Approved |
0.5812 | Remote Similarity | NPD4734 | Approved |
0.5812 | Remote Similarity | NPD4735 | Approved |
0.5809 | Remote Similarity | NPD803 | Phase 1 |
0.5806 | Remote Similarity | NPD3387 | Approved |
0.5806 | Remote Similarity | NPD453 | Phase 1 |
0.5806 | Remote Similarity | NPD452 | Phase 1 |
0.5794 | Remote Similarity | NPD1312 | Approved |
0.5785 | Remote Similarity | NPD1721 | Clinical (unspecified phase) |
0.5785 | Remote Similarity | NPD1342 | Approved |
0.5778 | Remote Similarity | NPD9305 | Clinical (unspecified phase) |
0.5776 | Remote Similarity | NPD9353 | Approved |
0.5772 | Remote Similarity | NPD2521 | Approved |
0.5772 | Remote Similarity | NPD2519 | Approved |
0.5772 | Remote Similarity | NPD2518 | Approved |
0.5772 | Remote Similarity | NPD3565 | Approved |
0.5772 | Remote Similarity | NPD3036 | Approved |
0.5772 | Remote Similarity | NPD2150 | Discontinued |
0.5772 | Remote Similarity | NPD3566 | Approved |
0.5764 | Remote Similarity | NPD4351 | Clinical (unspecified phase) |
0.576 | Remote Similarity | NPD5629 | Discontinued |
0.5752 | Remote Similarity | NPD1333 | Phase 3 |
0.5752 | Remote Similarity | NPD1702 | Phase 3 |
0.5752 | Remote Similarity | NPD1394 | Approved |
0.575 | Remote Similarity | NPD3545 | Approved |
0.575 | Remote Similarity | NPD3546 | Approved |
0.5745 | Remote Similarity | NPD758 | Approved |
0.5739 | Remote Similarity | NPD716 | Approved |
0.5738 | Remote Similarity | NPD1107 | Approved |
0.5738 | Remote Similarity | NPD1108 | Approved |
0.5732 | Remote Similarity | NPD7032 | Approved |
0.5725 | Remote Similarity | NPD3462 | Approved |
0.5725 | Remote Similarity | NPD1561 | Phase 2 |
0.5725 | Remote Similarity | NPD3461 | Approved |
0.5724 | Remote Similarity | NPD5551 | Clinical (unspecified phase) |
0.5723 | Remote Similarity | NPD676 | Discontinued |
0.5714 | Remote Similarity | NPD2925 | Approved |
0.5714 | Remote Similarity | NPD1262 | Discovery |
0.5714 | Remote Similarity | NPD2924 | Approved |
0.5703 | Remote Similarity | NPD922 | Approved |
0.5702 | Remote Similarity | NPD4114 | Approved |
0.5702 | Remote Similarity | NPD4115 | Approved |
0.5694 | Remote Similarity | NPD9469 | Approved |
0.5692 | Remote Similarity | NPD678 | Discontinued |
0.568 | Remote Similarity | NPD2914 | Approved |
0.568 | Remote Similarity | NPD2913 | Approved |
0.568 | Remote Similarity | NPD1175 | Approved |
0.568 | Remote Similarity | NPD2587 | Approved |
0.5659 | Remote Similarity | NPD1479 | Clinical (unspecified phase) |
0.5659 | Remote Similarity | NPD1306 | Clinical (unspecified phase) |
0.5652 | Remote Similarity | NPD4649 | Clinical (unspecified phase) |
0.5652 | Remote Similarity | NPD412 | Approved |
0.5641 | Remote Similarity | NPD2875 | Clinical (unspecified phase) |
0.5639 | Remote Similarity | NPD1324 | Clinical (unspecified phase) |
0.5638 | Remote Similarity | NPD2603 | Clinical (unspecified phase) |
0.5635 | Remote Similarity | NPD4085 | Approved |
0.5634 | Remote Similarity | NPD1902 | Approved |
0.5634 | Remote Similarity | NPD680 | Discontinued |
0.5634 | Remote Similarity | NPD1904 | Approved |
0.563 | Remote Similarity | NPD1396 | Approved |
0.5625 | Remote Similarity | NPD1057 | Approved |
PubChem CID   | 13624 |
ChEMBL   | CHEMBL305513 |
ZINC   |
Molecular Weight:   | 133.06 |
ALogP:   | -0.4695 |
MLogP:   | 1.9 |
XLogP:   | 2.148 |
# Rotatable Bonds:   | 0 |
Polar Surface Area:   | 47.91 |
# H-Bond Aceptor:   | 3 |
# H-Bond Donor:   | 3 |
# Rings:   | 2 |
# Heavy Atoms:   | 10 |